Skip to main content

Research Repository

Advanced Search

Genetic basis for personalized medicine in asthma

Portelli, Michael A.; Sayers, Ian



There is heterogeneity in patient responses to current asthma medications. Significant progress has been made identifying genetic polymorphisms that influence the efficacy and potential for adverse effects to asthma drugs, including; β2-adrenergic receptor agonists, corticosteroids and leukotriene modifiers. Pharmacogenetics holds great promise to maximise clinical outcomes and minimize adverse effects. Asthma is heterogeneous with respect to clinical presentation and inflammatory mechanisms underlying the disease, which is likely to contribute to variable results in clinical trials targeting specific inflammatory mediators. Genome-wide association studies have begun to identify genes underlying asthma (e.g., IL1RL1), which represent future therapeutic targets. In this article, we review and update the pharmacogenetics of current asthma therapies and discuss the genetics underlying selected Phase II and future targets.


Portelli, M. A., & Sayers, I. (2012). Genetic basis for personalized medicine in asthma. Expert Review of Respiratory Medicine, 6(2), doi:10.1586/ers.12.9

Journal Article Type Article
Publication Date Apr 1, 2012
Deposit Date Mar 27, 2014
Publicly Available Date Mar 27, 2014
Journal Expert Review of Respiratory Medicine
Print ISSN 1747-6348
Electronic ISSN 1747-6348
Publisher Taylor & Francis
Peer Reviewed Peer Reviewed
Volume 6
Issue 2
Public URL
Publisher URL


Line_85_Genetic_basis_for_personalized....pdf (1.1 Mb)

Copyright Statement
Copyright information regarding this work can be found at the following address:

You might also like

Downloadable Citations